Four Parallel Marketing Authorization Pathways for Medical Devices in Ethiopia

1. Key takeaways

Ethiopian medical device market entry runs through four parallel pathways: Full Assessment, the Stringent Regulatory Authority (SRA) / WHO PQ / UNFPA PQ route, the low-risk notification procedure (Low-risk), and Special Access import (Special Access). The four pathways differ in their eligibility conditions, the depth of documentation they demand, and the focus of the review once the file arrives — but they share a single endpoint: obtaining a marketing authorization, or an approved import in the cases where registration is waived.

The decision sequence for pathway selection should be: first test whether registration is waived; then test whether the product belongs on the low-risk list; then test whether SRA or prequalification evidence exists; and only last, prepare a Full Assessment. Each earlier gate in that sequence is cheaper and faster than the one after it, so exhausting the waiver and reliance options before committing to a full dossier is not merely good practice — it is the structure the guidance itself contemplates. Working the sequence backwards, by defaulting to Full Assessment and hoping to downgrade later, wastes screening fees and calendar time, and in the worst case costs the entire application, because a deliberately mislabeled submission is rejected outright rather than transferred to a different pathway.

2. Legal basis

3. Expert insights

Insight 1: the triage logic across the four pathways is risk combined with existing external evidence. Full Assessment is aimed at medium- and high-risk products that carry no external approval evidence; the SRA route is aimed at products already approved by a stringent regulatory authority or prequalified by an international organization; the low-risk route is aimed at Class I / Class A products that are neither sterile nor measuring; and Special Access is aimed at the four statutory categories exempt from registration. This triage is precisely the proportionality principle of Article 19(1) put into operational form: the heavier the risk, the heavier the scrutiny, and the more external evidence a product already holds, the less Ethiopia needs to generate that evidence itself through its own review resources.

Insight 2: the SRA route does not reduce the number of dossier items; it changes the focus of the review. Section 9.4 of the general guidelines states explicitly that the applicant must still submit the complete set of applicable administrative and technical documents required under the Full Assessment pathway, but that processing time is shorter, because the review focuses on verifying the authenticity of the information submitted. Reading the route as halving the paperwork is a serious misjudgment: the file that reaches EFDA is the same size, and only the depth of scientific re-examination differs. Teams that trim the dossier for an SRA submission routinely fail screening for incompleteness, losing the very time advantage the route was meant to deliver.

Insight 3: the SRA route preserves the discretion to convert to Full Assessment. The general guidelines note that an approval granted by the country of origin provides a certain level of assurance of quality, safety and performance, but may not provide the same assurance when the device is used in Ethiopia; for that reason, where the authority considers it necessary, it may conduct a complete evaluation and request supplementary information. Choosing the fast lane therefore does not mean the possibility of in-depth review is surrendered. The technical dossier must remain ready to withstand a full evaluation at any point in the process, and the project plan should reserve capacity for responding to supplementary information requests.

Insight 4: the low-risk route carries explicit exclusions. Section 3 of EFDA-GDL-092 provides that the route applies to the Class A IVD devices and Class I non-IVD devices included on the official list, and does not apply to all sterile devices and most measuring devices. The inference that every Class I device automatically qualifies for the low-risk route is wrong: sterility and measurement are two independent exclusion conditions, and either one alone can remove an otherwise eligible product from the route. A product that is Class I but supplied sterile, or Class I with a measuring function, falls outside the simplified arrangement entirely.

Insight 5: the cost of selecting the wrong pathway is rejection of the entire submission. Section 9.4 further provides that if an applicant intentionally submits misleading information (presenting a non-SRA application as an SRA application), the application will be rejected directly at the screening or evaluation stage rather than transferred to another pathway. Pathway selection is therefore a compliance judgment that must be documented and traceable: keep the reasoning, the supporting evidence and the classification rationale on file, because both the screening reviewers and any subsequent audit will ask why a particular route was chosen.

4. Practical recommendations

1. Apply the sequence waiver, then low-risk, then SRA, then Full Assessment: work through the gates in order and never apply the sequence in reverse.
2. For the SRA route, submit against the complete checklist: expect only a shorter timeline, not a lighter file.
3. For the low-risk pathway, verify the exclusion items first: sterile and measuring devices do not qualify.
4. Keep a written justification and supporting evidence for the pathway selection: it will be needed to answer later queries.
5. Never mislabel a pathway for the sake of speed: misleading submissions are rejected outright.
6. For multi-product submissions, prepare to the highest applicable pathway requirement: this avoids batch-by-batch rejections.

5. Verification checklist

• □ Possibility of a registration-waiver special access route has been ruled out
• □ Low-risk list and the two exclusion conditions of sterility and measurement have been checked
• □ SRA or WHO / UNFPA prequalification evidence has been collected
• □ Documents have been prepared against the complete Full Assessment checklist, whichever pathway is chosen
• □ The reasons for the pathway selection have been recorded in writing and archived

Regulatory information verified as of October 29, 2026. The four pathways and their eligibility conditions described in this article follow the current text of Sections 9 and 10 of EFDA-GDL-046; when the guidance is updated, the content must be re-verified.

• Ethiopia local resource: GRZAN supports manufacturers from the Chinese mainland and overseas in working with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA) applications, the institutional competency certificate (CoC) and import permit applications, including local agent scheme design and agency agreement review, SRA reliance route justification, UMDN coding and classification determination, technical dossier preparation, and vigilance and post-market surveillance system setup.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility determination, Essential Principles conformity justification, English-language labeling and instructions-for-use localization, vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn. For EFDA registration pathway and classification strategy support for the Ethiopian market, write to info@grzanglobal.com.